argenx (NASDAQ: ARGX) — Perfil da empresa, notícias e dados financeiros
argenx is a biotechnology company developing antibody-based therapies for autoimmune diseases and cancer, focusing on innovative patient solutions.
argenx
argenx is a global immunology company focused on improving the lives of patients suffering from severe autoimmune diseases. The company discovers, develops, and commercializes novel antibody-based therapies designed to target autoimmune pathology through its proprietary antibody innovation ecosystem. Its primary product, VYVGART (efgartigimod), is a neonatal Fc receptor (FcRn) blocker approved for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with additional formulations including VYVGART Hytrulo. argenx collaborates with academic and industrial research partners to discover novel targets, advance disease pathways, and progress candidate therapies through clinical development across global markets.
Resumo
Operações
Produtos e/ou serviços de argenx
- Intravenous Neonatal Fc Receptor Blockers: Intravenous formulations targeting neonatal Fc receptors to reduce pathogenic IgG antibodies, approved for treating generalized myasthenia gravis in adult patients across major pharmaceutical markets including the United States, Europe, Japan, and Canada.
- Subcutaneous Neonatal Fc Receptor Blockers: Subcutaneous co-formulated antibody therapeutics combined with recombinant human hyaluronidase, approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy to enable self-administration or reduced infusion duration in clinical settings.
- Complement C2 Inhibitors: Humanized sweeping monoclonal antibodies designed to selectively inhibit complement component C2 and downstream complement pathway activation, currently undergoing clinical trials and development for severe IgM-driven autoimmune conditions in global patient populations.
- Antibody Innovation Ecosystem: Collaborative research initiatives with academic medical centers and biopharmaceutical partners to discover novel target pathways, engineer differentiated monoclonal antibody candidates, and translate early-stage immunology discoveries into clinical pipelines.
- Externally Sponsored Research Programs: Global investigator-initiated clinical trial collaborations evaluating neonatal Fc receptor inhibition and complement-targeting therapeutic candidates across expanded autoimmune indications, including hematologic, neuromuscular, nephrologic, and dermatologic disease categories in patient populations worldwide.
- Commercial Distribution and Market Access: Integrated commercialization infrastructure, specialty medical operations, and global distribution networks delivering target-specific immunology therapeutics to patients, medical centers, and healthcare providers across North America, Europe, Asia-Pacific, and Latin America.
equipe executiva do argenx
- Timothy Van HauwermeirenCo-Founder & Non-Independent Non-Executive Chairman of the Board
- Karen MasseyCEO & Executive Director
- Karl GubitzChief Financial Officer
- Peter UlrichtsChief Scientific Officer
- Malini MoorthyGeneral Counsel & Corporate Secretary
- Arjen LemmenVP of Corporate Development & Strategy
- Andria WilkGlobal Head of Quality
- Luc TruyenChief Medical Officer
- Hans de Haard IrCo-Founder & Member of Board Advisors
- Filip BorgionsChief Technology Innovation Officer
Últimas notícias sobre a argenx
argenx Q3 product sales rise 54% to $1.7 billion
United Statesargenx FB102 meets Phase 2 endpoint
United Statesargenx ends Phase 3 Sjögren's study
United Statesargenx reports 15.4-point gain in ALKIVIA trial
United Statesargenx to buy Forte Biosciences for $2.2 billion
United Statesargenx VYVGART revenue climbs 60% to $1.5 billion
United States
Principais indicadores financeiros
Resultados divulgados pela argenx , em USD.
- Cap. de mercado
- 56,1 bi
- Receita (TTM)
- 5,9 bi
- P/L
- 30.9
- LPA (diluído, TTM)
- 28.9
- Dividend yield
- —
- Margem de lucro
- 31.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,2 bi | 1,1 bi | 1,3 bi | |
| 2,2 bi | -21,7 mi | 833 mi | |
| 1,2 bi | -425 mi | -295,1 mi | |
| 410,7 mi | -720,3 mi | -709,6 mi |